← Human Trials & Peer-Reviewed Studies
Daily Folic Acid and/or Vitamin B12 Supplementation Between 6 and 30 Months of Age and Cardiometabolic Risk Markers After 6-7 Years: A Follow-Up of a Randomized Controlled Trial
Plain-language guide to PMID 36889645 (2023): double-blind randomized controlled trial study of Cyanocobalamin (Vitamin B12).
Key Facts
- PMID
- 36889645
- Journal
- The Journal of nutrition
- Year
- 2023
- Study type
- Randomized Controlled Trial
- Authors
- Manapurath R et al. (7 authors)
- DOI
- 10.1016/j.tjnut.2023.03.003
What This Study Did, in Plain Language
What Was Tested
Researchers studied Cyanocobalamin (Vitamin B12) in this randomized controlled trial publication.
The researchers investigated the effect of supplementation of vitamin B12 with or without folic acid for 6 mo in early childhood on cardiometabolic risk markers after 6-7 y.
Why It Was Studied
Gov as NCT00717730, and the follow-up study at www.ctri.nic.in as CTRI/2016/11/007494.
Who Took Part
PubMed indexes the participants as young children and children.
This is a follow-up study of a 2 × 2 factorial, double-blind, randomized controlled trial of vitamin B12 and/or folic acid supplementation in 6-30-mo-old children.
Enrolled children were contacted again after 6 y (September 2016-November 2017), and plasma concentrations of tHcy, leptin, high molecular weight adiponectin, and total adiponectin were measured (N = 791).
How the Study Was Run
The design is described as randomized and double-blind.
Random assignment meant chance, not the researchers, decided who got Cyanocobalamin (Vitamin B12) and who got the comparison, which limits bias.
As a double-blind Cyanocobalamin (Vitamin B12) study, the assignments were hidden from both participants and investigators until the end.
What Was Measured
PubMed files the paper under topics including Folic Acid, Vitamin B 12, Leptin, Adiponectin, Dietary Supplements and Homocysteine.
Author keywords: B vitamins, cardiovascular diseases, metabolic markers and young children.
What This Means in Plain Language
The paper is a randomized and double-blind study of Cyanocobalamin (Vitamin B12).
Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2023 (The Journal of nutrition), a journal based in United States.
More context: the Cyanocobalamin (Vitamin B12) compound page, all human trials.
Our Notes on the Compound
Cyanocobalamin (Vitamin B12): A synthetic form of vitamin B12 (cobalamin), an essential nutrient for DNA synthesis, red blood cell formation and neurological function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.